Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention.
OBJECTIVE
To investigate the spontaneous occurrence of circulating mesenchymal stem cells (MSC) and angiogenic factors in patients with ST elevation acute myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).


METHODS
In 20 patients with STEMI, blood samples were obtained on days 1, 3, 7, 14, 21, and 28 after the acute PCI. Fifteen patients with a normal coronary angiography formed a control group. MSC (CD45-/CD34-), plasma stromal derived factor 1 (SDF-1), vascular endothelial growth factor A (VEGF-A), and fibroblast growth factor 2 (FGF-2) were measured by multiparametric flow cytometry and enzyme linked immunosorbent assay (ELISA).


RESULTS
Circulating CD45-/CD34- cells were significantly decreased on day 7 compared with day 3. Cell counts normalised one month after the acute onset of STEMI. The changes were mainly seen in patients with a large infarction. Plasma SDF-1 increased significantly from day 3 to day 28, and VEGF-A and FGF-2 increased significantly from day 7 to day 28.


CONCLUSIONS
Spontaneous sequential fluctuations in MSC and the increase in vascular growth factor concentrations after STEMI suggest that the optimal time for additional stem cell therapy is three weeks after a myocardial infarction to obtain the maximum effects by stimulating endogenous growth factors on the delivered stem cells.
Wang
Y
Y
Medical Department B, The Heart Centre, University Hospital, Rigshospitalet, Copenhagen, Denmark.
Johnsen
H E
HE
Mortensen
S
S
Bindslev
L
L
Ripa
R Sejersten
RS
Haack-Sørensen
M
M
Jørgensen
E
E
Fang
W
W
Kastrup
J
J
D015906:Angioplasty, Balloon, Coronary; D016022:Case-Control Studies; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000473:pathology / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D011184:Postoperative Period; D019089:Stem Cell Factor / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D019089:Stem Cell Factor; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2